{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-017983","form_type":"8-K","ticker":"FEMY","cik":"0001339005","company_name":"FEMASYS INC","filed_at":"2025-05-08T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.017413+00:00","generated_at":"2026-05-22T03:36:45.889678+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Femasys Q1 sales up 25.9% but net loss widens to $5.9M; cash runway only into early Q3 2025","bullets":["Sales increased 25.9% YoY to $341K, driven by FemaSeed sales.","Net loss widened to $5.9M ($0.23 per share) from $3.6M ($0.17) in prior year.","R&D expenses surged 67.6% to $2.97M, mainly due to regulatory and development costs.","Cash and equivalents $3.8M; company expects to fund operations only into early Q3 2025.","FemBloc delivery system received CE mark recommendation in Europe; FemaSeed partnerships expanded."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-017983","json":"https://secwatch.observer/filing/0001140361-25-017983.json","markdown":"https://secwatch.observer/filing/0001140361-25-017983.md","text":"https://secwatch.observer/filing/0001140361-25-017983.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125017983/0001140361-25-017983-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339005/000114036125017983/ef20048606_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T03:36:45.889678+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}